Whole-heart radiation therapy for advanced heart failure
Part of Heart & circulation clinical trials.
This trial tests if a low dose of radiation to the whole heart can help people with very advanced heart failure. It is for people who have severe symptoms despite maximum medications and are not candidates for a heart pump or transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have end-stage heart failure with symptoms even when resting or with light activity (NYHA class 3 or 4)
- Your heart's pumping strength is very low (LVEF of 30% or less)
- A blood test shows a high level of NT-Pro-BNP (1500 pg/mL or more)
- You are already on the best available heart failure medications but still getting worse
- You are not eligible for a left ventricular assist device or heart transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a low dose of radiation to the heart can help people with advanced heart failure feel better and improve heart function. It is for patients whose heart failure is stable but severe, and who are already on the best medications.
This trial tests whether a targeted, low-dose radiation treatment to the heart can improve symptoms and outcomes for people with advanced heart failure who cannot have a heart transplant or a mechanical heart pump. The treatment is given as a one-time procedure and aims to reduce the heart's workload and improve its function.
This trial tests a very low dose of radiation to see if it can improve symptoms in people with heart failure that hasn't gotten better with standard medicines. The radiation is aimed at the heart to reduce inflammation and may help you feel better.
This trial tests a new way to plan radiation for cancers in the chest area (like lung, esophageal, or thymus cancers) that aims to protect the heart from high doses of radiation. It is for people who need daily radiation for at least three weeks and who are expected to live more than a year.
This trial tests an early heart-focused intervention guided by a special heart recording (impedance cardiography) in people with locally advanced, unresectable stage III non-small cell lung cancer. The goal is to improve heart-related safety during planned radiation and chemotherapy, with or without immunotherapy.
This trial is studying a non-surgical (conservative) treatment approach for people being considered for a left ventricular assist device (LVAD). It may help some patients who are too sick or unable to tolerate standard heart failure medicines, but it will only match people with specific heart function and health-test results.
Hear when a new Heart Failure NYHA Class III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.